BEN FIRSCHEIN

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; provisions affecting categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act; all provisions - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards.

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

-Advise on standards-setting, verification, supply chain, overseas programs and quality of medicines -Activities related to drugs, dietary supplements, biologics and food ingredients.-Implementation of Public Law 112144; Food and Drug Administration Safety and Innovation Act of 2012; -Implementation of Public Law 111-148; Patient Protection and Affordable Care Act; categories and classes - USP model guidelines and essential health benefits. -Implementation of Public Law No: 112-144; Food Safety Modernization Act -Implementation of Public Law: 111-148; Biologic Price Competition and Innovation Act - HR 3204/and S. __; Drug Quality and Security Act; provisions related to compounding standards. -S. 959, Pharmaceutical Compounding Quality and Accountability Act

- Advise on standards-setting, verification, overseas programs, and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. - Comments to FDA on implementation of the Food Safety Modernization Act. - Letter to CMS regarding partnership for patients. - S. 1310, "Dietary Supplement Labeling Act of 2011", regarding all provisions. - H.R. 1483, "Drug Safety Enhancement Act of 2011", regarding Section 102 on drug supply quality and safety. - Comments to the FDA on streamlining and updating regulations.

- Advise on standards-setting, verification, overseas programs, and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. - Implementation of the Food Safety Modernization Act. - Issues regarding creating and updating monographs. - Issues regarding FDA funding. - S 1584, "Drug Safety Accountability Act of 2011", regarding advice on drug quality. - HR 1483, "Drug Safety Enhancement Act of 2011", regarding advice on drug quality.

- Advise on standards-setting, verification, overseas programs, and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. - H.R. 1483, "Drug Safety Enhancement Act of 2011", regarding Section 102 on drug supply quality and safety. - H.R. 2227, "Medical Gas Safety Act", regarding Section 3, Regulation of Medical Gases. - H. 2112, "Agriculture Appropriations Bill, FY 2012", regarding support for FDA funding.

- Advise on standards-setting, verification, overseas programs, and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. - H.R. 1483, "Drug Safety Enhancement Act of 2011", regarding Section 102 on drug supply quality and safety. - H.R. 2227, "Medical Gas Safety Act", regarding Section 3, Regulation of Medical Gases. - H. 2112, "Agriculture Appropriations Bill, FY 2012", regarding support for FDA funding.

- Advise on standards-setting, verification, overseas programs, and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. - S. 3690, "Drug Quality and Safety Enhancement Act", regarding comments related to standards-setting for drugs and verification programs. - Comments on medication errors with respect to docket # FDA-2010-N-0168. - Communications in support of FDA funding.

-H.R. 3590, "Patient Protection and Affordable Care Act"; provisions relating to follow on biologics and general issues of interest. -Advise on drug/food/dietary supplement/packaging standards-setting activities of USP. -Seek Congressional recognition of national standards. -Seek to educate/support Congress on USAID programs to advance quality drugs, and support USP verification programs.

-Advise on drug/food/dietary supplement/packaging standards-setting activities of USP. -Seek Congressional recognition of national standards. -Seek to educate/support Congress on USAID programs to advance quality drugs, and support USP verification programs. -Drug quality legislation (pending), regarding compendial modernization/import safety. -FY 2011 FDA Appropriations, regarding provisions related to third-party certification and general support for mission. -H.R. 3590, "Patient Protection and Affordable Care Act"; provisions relating to follow on biologics and general issues of interest.

-H.R. 3590, "Patient Protection and Affordable Care Act"; issues related to implementation and USP-related programs. - Advise on standards-setting, verification, overseas programs, and quality of medicines activiites related to drugs, dietary supplements, biologics and food ingredients.

- Advise on standards-setting, verification, overseas programs, and quality of medicines activiites related to drugs, dietary supplements, biologics and food ingredients. - HR 5116, "America Competes Act" (Reauthorization), regarding a recommendation to include work with nonprofit organizations in the list of NIST criteria for funding reference standards development. -Communications regarding the role and importance of standards; relation of USP standards to voluntary consensus standards. -Communications regarding the importance of strengthening USP's relationship with the FDA/Stakeholders to maintain up-to-date national standards. -Communications regarding updates on USP's USAID-funded activities, USP convention activities and resolutions.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues regarding intellectual property issues for drugs. -HR 1298 "Pharmaceutical Market Access & Drug Safety Act of 2009", regarding all provisions on the effect of re-importation provisions on FDA requirements and USP Compendial Standards for Drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -HR 1427 / S 726 "Promoting Innovation and Access to Lifesaving Medicine Act", regarding all provisions on biologics; role and importance of standards, follow-on biologics. -HR 1548 "Pathway for Biosimilars Act", regarding all provisions on biologics; role of importance of standards, follow-on biologics. -HR 1105 "FY 2009 Omnibus Appropriations Act", regarding provisions on verification programs, standards and resources for FDA.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues regarding intellectual property issues for drugs. -HR 1298 "Pharmaceutical Market Access & Drug Safety Act of 2009", regarding all provisions on the effect of re-importation provisions on FDA requirements and USP Compendial Standards for Drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -HR 1427 / S 726 "Promoting Innovation and Access to Lifesaving Medicine Act", regarding all provisions on biologics; role and importance of standards, follow-on biologics. -HR 1548 "Pathway for Biosimilars Act", regarding all provisions on biologics; role of importance of standards, follow-on biologics. -HR 1105 "FY 2009 Omnibus Appropriations Act", regarding provisions on verification programs, standards and resources for FDA.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues regarding intellectual property issues for drugs. -HR 1298 "Pharmaceutical Market Access & Drug Safety Act of 2009", regarding all provisions on the effect of re-importation provisions on FDA requirements and USP Compendial Standards for Drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -HR 1427 / S 726 "Promoting Innovation and Access to Lifesaving Medicine Act", regarding all provisions on biologics; role and importance of standards, follow-on biologics. -HR 1548 "Pathway for Biosimilars Act", regarding all provisions on biologics; role of importance of standards, follow-on biologics. -HR 1105 "FY 2009 Omnibus Appropriations Act", regarding provisions on verification programs, standards and resources for FDA.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

- HR 1859, "Independent Drug Education & Outreach Act", regarding all provisions as a neutral, expert scientific resource. - S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. - Issues relating to heparin. - Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals, specifically to update Congress on USP standards. - Information on follow-on biologics. - Information on drug quality as a neutral, expert scientific resource.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -HR 2502/ S 1213, "Comparative Effectiveness Research Act", regarding all provisions, specifically organizations eligible for grants related to comparative effectiveness research. -Healthcare reform bill regarding provisions relating to comparative effectiveness. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

- S 510 "FDA Food Safety Modernization Act", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - HR 2749 "Food Safety Enhancement Act", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - Communications on food quality.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -Agriculture Appropriations Bill regarding support funding for the Food and Drug Administration. -Issues regarding melamine and food ingredient standards. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

- HR 3200, "America's Affordable health Choice Act of 2009", regarding the amendment on public option/ formularies, specifically, advise on USP's role with MMA Model Guidelines.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -HR 2502/ S 1213, "Comparative Effectiveness Research Act", regarding all provisions, specifically organizations eligible for grants related to comparative effectiveness research. -Healthcare reform bill regarding provisions relating to comparative effectiveness. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -Consultation on model guidelines, Medicare Modernization Act. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -HR 2502/ S 1213, "Comparative Effectiveness Research Act", regarding all provisions, specifically organizations eligible for grants related to comparative effectiveness research. -Healthcare reform bill regarding provisions relating to comparative effectiveness. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -Consultation on model guidelines, Medicare Modernization Act. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

- S 510 "FDA Food Safety Modernization Act", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - HR 2749 "Food Safety Enhancement Act", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - Communications on food quality.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues regarding intellectual property issues for drugs. -HR 1298 "Pharmaceutical Market Access & Drug Safety Act of 2009", regarding all provisions on the effect of re-importation provisions on FDA requirements and USP Compendial Standards for Drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -HR 1427 / S 726 "Promoting Innovation and Access to Lifesaving Medicine Act", regarding all provisions on biologics; role and importance of standards, follow-on biologics. -HR 1548 "Pathway for Biosimilars Act", regarding all provisions on biologics; role of importance of standards, follow-on biologics. -HR 1105 "FY 2009 Omnibus Appropriations Act", regarding provisions on verification programs, standards and resources for FDA.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -Agriculture Appropriations Bill regarding support funding for the Food and Drug Administration. -Issues regarding melamine and food ingredient standards. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of the FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to President Obama regarding food safety. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues with respect to intellectual property issues for drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

- S 510 "FDA Food Safety Modernization Act", regarding all provisions, specifically advice to Congress on food ingredient standards in food safety legislation. - HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding all provisions, specifically advice to Congress on food ingredient standards in food safety legislation. -Advise on drug/food standards-setting activities of USP, including USP-NF, FCC, heparin, caps and ferrules.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of the FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to President Obama regarding food safety. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -S 510 "FDA Food Safety Modernization Act", regarding all provisions with respect to food ingredient quality.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -HR 2502/ S 1213, "Comparative Effectiveness Research Act", regarding all provisions, specifically organizations eligible for grants related to comparative effectiveness research. -Healthcare reform bill regarding provisions relating to comparative effectiveness. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -HR 2502/ S 1213, "Comparative Effectiveness Research Act", regarding all provisions, specifically organizations eligible for grants related to comparative effectiveness research. -Healthcare reform bill regarding provisions relating to comparative effectiveness. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -Consultation on model guidelines, Medicare Modernization Act. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

- Issues relating to heparin. - S. 301, "Physician Payment Sunshine Act", regarding all provisions - Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals, specifically to update Congress on USP standards.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -Consultation on model guidelines, Medicare Modernization Act. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 574/ S 254, "Medicare Home Infusion Therapy Coverage Act of 2009", regarding section requesting USP to develop standards and formulary. -HR 684/ S 330, "Medicare Prescription Drug Savings and Choice Act of 2009", regarding sections cross referencing USP role with model guidelines under Part D. -HR 2502/ S 1213, "Comparative Effectiveness Research Act", regarding all provisions, specifically organizations eligible for grants related to comparative effectiveness research. -Healthcare reform bill regarding provisions relating to comparative effectiveness. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

- S 510 "FDA Food Safety Modernization Act", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - HR 2749 "Food Safety Enhancement Act", regarding all provisions with specific reference to standards on ingredients and dietary supplements. - Communications on food quality.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of the FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to President Obama regarding food safety. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -S 510 "FDA Food Safety Modernization Act", regarding all provisions with respect to food ingredient quality.

- S 510 "FDA Food Safety Modernization Act", regarding all provisions, specifically advice to Congress on food ingredient standards in food safety legislation. - HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding all provisions, specifically advice to Congress on food ingredient standards in food safety legislation. -Advise on drug/food standards-setting activities of USP, including USP-NF, FCC, heparin, caps and ferrules.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -Agriculture Appropriations Bill regarding support funding for the Food and Drug Administration. -Issues regarding melamine and food ingredient standards. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

- HR 1859, "Independent Drug Education & Outreach Act", regarding all provisions as a neutral, expert scientific resource. - S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. - Issues relating to heparin. - Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals, specifically to update Congress on USP standards. - Information on follow-on biologics. - Information on drug quality as a neutral, expert scientific resource.

-GAO Study on Dietary Supplement Regulation, provided comments for. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on drugs and food ingredients with specific reference to drug quality, food quality and compendial modernization. -Letter to DHHS Secretary Designate regarding FDA Mission on drug quality, food quality, standards and follow-on biologics. -Letter to Acting Commissioner of FDA regarding FDA budget and standards. -Communication with Congress on standards of use for heparin and glycerin. -Communication with FDA regarding drug quality, food quality and follow-on biologics and FDA resources. -Letter to Congress on legislative issues before Congress regarding drug quality, food quality and follow-on biologics and FDA resources. -Provided information to Congress for a hearing on drug issues regarding intellectual property issues for drugs. -HR 1298 "Pharmaceutical Market Access & Drug Safety Act of 2009", regarding all provisions on the effect of re-importation provisions on FDA requirements and USP Compendial Standards for Drugs. -Letter to FDA Commissioner-Designate regarding FDA resources, drug quality and food quality. -HR 1427 / S 726 "Promoting Innovation and Access to Lifesaving Medicine Act", regarding all provisions on biologics; role and importance of standards, follow-on biologics. -HR 1548 "Pathway for Biosimilars Act", regarding all provisions on biologics; role of importance of standards, follow-on biologics. -HR 1105 "FY 2009 Omnibus Appropriations Act", regarding provisions on verification programs, standards and resources for FDA.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-S 510 "FDA Food Safety Modernization Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 759 "The Food and Drug Administration Globalization Act of 2009", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 2749 "Food Safety Enhancement Act", regarding provisions on food ingredients with specific reference to standards, certification, verification, adulteration and contamination. -HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission.

-HR 1859/ S 767, "Independent Drug Education & Outreach Act", regarding all provisions, specifically standards relating to academic detailing. -HR 1427/S 726, "Promoting Innovation and Access to Lifesaving Medicine Act, regarding all provisions. -HR 1548, "Pathway for Biosimilars Act", regarding all provisions. -HR 1298/ S 525, "Pharmaceutical Market Access and Drug Safety Act of 2009", regarding all provisions in supporting the FDA and compendial standards for drugs (reimportation and importation). -Issues relating to Heparin, consultation on heparin and compendial standards. -S 882, "Drug and Device Accountability Act of 2009", regarding section 111 in support of compedial modernization. -S 369, "The Preserving Access to Affordable Generic Drugs Act", regarding all provisions. -Consultation regarding exclusivity in drug law. -Information regarding USP General Chapter <1> Injections - labeling on ferrules and cap overseals. -Outreach to House and Senate staff to explain USP's standards setting mission. -Outreach to Administration to explain USP's standards setting mission. -Communications with Congress regarding USP China MOU re: drugs.

-H.R. 3590, "Patient Protection and Affordable Care Act"; provisions relating to insurance exchanges/formularies, specifically advise on USP role in Medicare Modernization Act Model Guidelines as they relate to healthcare. -H.R. 3962, "Affordable Healthcare for America Act", provisions relating to insurance exchanges/formularies, specifically advise on USP role in Medicare Modernization Act Model Guidelines as they relate to healthcare. - Academic detailing.

-H.R. 3590, "Patient Protection and Affordable Care Act"; provisions relating to insurance exchanges/formularies, specifically advise on USP role in Medicare Modernization Act Model Guidelines as they relate to healthcare. -H.R. 3962, "Affordable Healthcare for America Act", provisions relating to insurance exchanges/formularies, specifically advise on USP role in Medicare Modernization Act Model Guidelines as they relate to healthcare. - Academic detailing.

-NO BILL NUMBER - Review revisions of FDA draft drug safety title, specific interest in the recognition of standards -S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-NO BILL NUMBER - Review revisions of FDA draft drug safety title, specific interest in the recognition of standards -S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions

-NO BILL NUMBER - Review revisions of FDA draft drug safety title, specific interest in the recognition of standards -S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions -S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-NO BILL NUMBER - Review revisions of FDA draft drug safety title, specific interest in the recognition of standards -S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions -S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions

-S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions -S. 3408: Comparative Effectiveness Research Act of 2008, Regarding all provisions -Review draft legislation on medication errors

-NO BILL NUMBER - Review revisions to FDA draft drug safety title, specific interest in the recognition of standards -S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions -S. 3408: Comparative Effectiveness Research Act of 2008, Regarding all provisions -Review draft legislation on medication errors

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions

-NO BILL NUMBER - Review revisions of FDA draft drug safety title, specific interest in the recognition of standards -S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions -S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions

-NO BILL NUMBER - Review revisions of FDA draft drug safety title, specific interest in the recognition of standards -S. 3385: FDA Food Safety and Modernization Act, Regarding all provisions -S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions -S. 3408: Comparative Effectiveness Research Act of 2008, Regarding all provisions -Review draft legislation on medication errors

Issues relating to advancing public health through public standards and related programs that help ensure the quality, safety and benefit of medicines and foods. Revised FDA draft drug safety title; S 3385: FDA Food Safety Modernization Act, all provisions; S 3396: Independent Drug Education Outreach Act of 2008, all provisions; S 3408, Comparative Effectiveness Research Act of 2008, all provisions; Draft legislation on medication errors; FDA draft guidance for industry: Voluntary Third Party Certification.

-NO BILL NUMBER - Review revisions to FDA draft drug safety title, specific interest in the recognition of standards -S. 3396: Independent Drug Education Outreach Act of 2008, Regarding all provisions -S. 3408: Comparative Effectiveness Research Act of 2008, Regarding all provisions -Review draft legislation on medication errors